View:

 

As filed with the Securities and Exchange Commission on March 17, 2017

Registration No. 333-    

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM S-8

 

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 


 

Catabasis Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 


 

Delaware

 

26-3687168

(State or Other Jurisdiction of
Incorporation or Organization)

 

(I.R.S. Employer
Identification No.)

 

One Kendall Square
Bldg. 1400E, Suite B14202
Cambridge, Massachusetts

 

02139

(Address of Principal Executive Offices)

 

(Zip Code)

 

2015 Stock Incentive Plan
2015 Employee Stock Purchase Plan

(Full Title of the Plan)

 

Jill C. Milne, Ph.D.
President and Chief Executive Officer
One Kendall Square

Bldg. 1400E, Suite B14202

Cambridge, Massachusetts 02139

(Name and Address of Agent For Service)

 

(617) 349-1971

(Telephone Number, Including Area Code, of Agent For Service)

 


 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer o

 

Accelerated filer o

 

 

 

Non-accelerated filer x  (Do not check if a smaller reporting company)

 

Smaller reporting company o

 


 

CALCULATION OF REGISTRATION FEE

 

 

 

 

 

 

 

 

 

 

Title of Securities
to be Registered

 

Amount
to be
Registered (1)

 

Proposed
Maximum
Offering
Price
Per Share

 

Proposed
Maximum
Aggregate
Offering Price

 

Amount of
Registration
Fee

 

Common Stock, $0.001 par value per share

 

940,877 shares

 

$

1.78

(2)

$

1,674,761.06

(2)

$

194.10

 

 

(1)              In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.

(2)              Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended, and based upon the average of the high and low prices of the Registrant’s Common Stock as reported on The Nasdaq Global Market on March 13, 2017.

 

 

 



 

Statement of Incorporation by Reference

 

This Registration Statement on Form S-8, relating to the 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan of Catabasis Pharmaceuticals, Inc. (the “Registrant”), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Accordingly, this Registration Statement incorporates by reference the contents of the Registration Statement on Form S-8, File No. 333-206394, filed with the Securities and Exchange Commission on August 14, 2015 by the Registrant, relating to the Registrant’s Amended and Restated 2008 Equity Incentive Plan, 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan, and the Registration Statement on Form S-8, File No. 333-210229, filed with the Securities and Exchange Commission on March 16, 2016 by the Registrant, relating to the Registrant’s 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan, except in each case for Item 8, Exhibits, with respect to which the Exhibit Index immediately preceding the exhibits attached hereto is incorporated herein by reference.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Cambridge, Commonwealth of Massachusetts, on this 17th day of March, 2017.

 

 

CATABASIS PHARMACEUTICALS, INC.

 

 

 

By:

/s/ Jill C. Milne

 

 

Jill C. Milne, Ph.D.

 

 

President and Chief Executive Officer

 

POWER OF ATTORNEY AND SIGNATURES

 

We, the undersigned officers and directors of Catabasis Pharmaceuticals, Inc., hereby severally constitute and appoint Jill C. Milne, Ph.D. and Deirdre A. Cunnane, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Catabasis Pharmaceuticals, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto. Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

 

Title

 

Date

 

 

 

 

 

/s/ Jill C. Milne

 

President and Chief Executive Officer and Director (Principal Executive Officer)

 

March 17, 2017

Jill C. Milne, Ph.D.

 

 

 

 

 

 

 

 

/s/ Deirdre A. Cunnane

 

Treasurer and General Counsel (Principal Financial Officer)

 

March 17, 2017

Deirdre A. Cunnane

 

 

 

 

 

 

 

 

/s/ Noah C. Clauser

 

Controller

 

March 17, 2017

Noah C. Clauser

 

 

 

 

 

 

 

 

 

/s/ Kenneth Bate

 

Co-Chairman of the Board of Directors

 

March 17, 2017

Kenneth Bate

 

 

 

 

 

 

 

 

 

/s/ Michael Ross

 

Co-Chairman of the Board of Directors

 

March 17, 2017

Michael Ross, Ph.D.

 

 

 

 

 

 

 

 

 

/s/ Burt Adelman

 

Director

 

March 17, 2017

Burt Adelman, M.D.

 

 

 

 

 

 

 

 

 

/s/ Nicholas Galakatos

 

Director

 

March 17, 2017

Nicholas Galakatos, Ph.D.

 

 

 

 

 

 

 

 

 

/s/ Jean George

 

Director

 

March 17, 2017

Jean George

 

 

 

 

 

 

 

 

 

/s/ Michael Kishbauch

 

Director

 

March 17, 2017

Michael Kishbauch

 

 

 

 

 

3



 

EXHIBIT INDEX

 

 

 

 

 

Incorporated by Reference

 

 

Exhibit
Number

 

Description of Exhibit

 

Form

 

File Number

 

Date of Filing

 

Exhibit
Number

 

Filed
Herewith

4.1

 

Restated Certificate of Incorporation of the Registrant

 

8-K

 

001-37467

 

July 1, 2015

 

3.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4.2

 

Amended and Restated By-Laws of the Registrant

 

8-K

 

001-37467

 

July 1, 2015

 

3.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5.1

 

Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

23.1

 

Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

23.2

 

Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

24.1

 

Power of attorney (included on the signature pages of this registration statement)

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

99.1

 

2015 Stock Incentive Plan

 

S-1

 

333-204144

 

June 3, 2015

 

10.7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

99.2

 

2015 Employee Stock Purchase Plan

 

S-1

 

333-204144

 

June 3, 2015

 

10.22

 

 

 

4


Exhibit 5.1

 

 

 

 

 

 

March 17, 2017

 

GRAPHIC

 

Catabasis Pharmaceuticals, Inc.
One Kendall Square
Bldg. 1400E, Suite B14202
Cambridge, MA 02139

 

Re:  Registration Statement on Form S-8: 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan

 

Ladies and Gentlemen:

 

We have assisted in the preparation of a Registration Statement on Form S-8 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), relating to an aggregate of 940,877 shares of common stock, $0.001 par value per share (the “Shares”), of Catabasis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issuable under the Company’s 2015 Stock Incentive Plan and 2015 Employee Stock Purchase Plan (the “Plans”).

 

We have examined the Certificate of Incorporation and By-Laws of the Company, each as amended and restated to date, and originals, or copies certified to our satisfaction, of all pertinent records of the meetings of the directors and stockholders of the Company, the Registration Statement and such other documents relating to the Company as we have deemed material for the purposes of this opinion.

 

In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, photostatic or other copies, the authenticity of the originals of any such documents and the legal competence of all signatories to such documents.

 

We assume that the appropriate action will be taken, prior to the offer and sale of the Shares in accordance with the Plans, to register and qualify the Shares for sale under all applicable state securities or “blue sky” laws.

 

We express no opinion herein as to the laws of any state or jurisdiction other than the state laws of the Commonwealth of Massachusetts, the General Corporation Law of the State of Delaware and the federal laws of the United States of America.

 

It is understood that this opinion is to be used only in connection with the offer and sale of the Shares while the Registration Statement is in effect.

 

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.

 

Based on the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the applicable Plan, the Shares will be validly issued, fully paid and nonassessable.

 

We hereby consent to the filing of this opinion with the Commission in connection with the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

 

 



 

Very truly yours,

 

 

 

WILMER CUTLER PICKERING

 

HALE AND DORR LLP

 

 

 

By:

/s/ Rosemary G. Reilly

 

 

Rosemary G. Reilly, a Partner

 

 


 

Exhibit 23.2

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2015 Stock Incentive Plan and the 2015 Employee Stock Purchase Plan of Catabasis Pharmaceuticals, Inc. of our report dated March 16, 2017, with respect to the consolidated financial statements of Catabasis Pharmaceuticals, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2016, filed with the Securities and Exchange Commission.

 

/s/ Ernst & Young LLP

 

 

 

Boston, Massachusetts

 

March 16, 2017